DE60209010D1 - Chimäre phagen - Google Patents

Chimäre phagen

Info

Publication number
DE60209010D1
DE60209010D1 DE60209010T DE60209010T DE60209010D1 DE 60209010 D1 DE60209010 D1 DE 60209010D1 DE 60209010 T DE60209010 T DE 60209010T DE 60209010 T DE60209010 T DE 60209010T DE 60209010 D1 DE60209010 D1 DE 60209010D1
Authority
DE
Germany
Prior art keywords
phages
protein
phage
helper
coat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60209010T
Other languages
English (en)
Other versions
DE60209010T2 (de
Inventor
Erwin Houtzager
Ton Logtenberg
Kruif Adriaan De
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Vaccines and Prevention BV
Original Assignee
Crucell Holand BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP01202304A external-priority patent/EP1266963A1/de
Priority claimed from US09/882,621 external-priority patent/US7070926B2/en
Application filed by Crucell Holand BV filed Critical Crucell Holand BV
Publication of DE60209010D1 publication Critical patent/DE60209010D1/de
Application granted granted Critical
Publication of DE60209010T2 publication Critical patent/DE60209010T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Holo Graphy (AREA)
DE60209010T 2001-06-15 2002-06-14 Chimäre phagen Expired - Lifetime DE60209010T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US882621 2001-06-15
EP01202304 2001-06-15
EP01202304A EP1266963A1 (de) 2001-06-15 2001-06-15 Chimäre Phagen
US09/882,621 US7070926B2 (en) 2001-06-15 2001-06-15 Chimaeric phages
PCT/NL2002/000391 WO2002103012A1 (en) 2001-06-15 2002-06-14 Chimaeric phages

Publications (2)

Publication Number Publication Date
DE60209010D1 true DE60209010D1 (de) 2006-04-13
DE60209010T2 DE60209010T2 (de) 2006-09-28

Family

ID=26076931

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60209010T Expired - Lifetime DE60209010T2 (de) 2001-06-15 2002-06-14 Chimäre phagen

Country Status (10)

Country Link
US (2) US7329530B2 (de)
EP (1) EP1402025B1 (de)
AT (1) ATE317009T1 (de)
AU (1) AU2002345421B2 (de)
CA (1) CA2449071C (de)
DE (1) DE60209010T2 (de)
DK (1) DK1402025T3 (de)
ES (1) ES2257560T3 (de)
NZ (1) NZ529465A (de)
WO (1) WO2002103012A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1402025T3 (da) 2001-06-15 2006-06-06 Crucell Holland Bv Kimære fager
US7070926B2 (en) 2001-06-15 2006-07-04 Crucell Holland B.V. Chimaeric phages
WO2003052053A2 (en) * 2001-12-17 2003-06-26 Ribapharm Inc. Nucleoside libraries and compounds by mcc combinatorial strategies on solid support
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
ES2442615T5 (es) 2002-07-18 2023-03-16 Merus Nv Producción recombinante de mezclas de anticuerpos
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
EP1639009B1 (de) 2003-05-30 2013-02-27 Merus B.V. Fab-bibliothek zur herstellung von einer mischung von antikörpern
WO2005000894A2 (en) 2003-06-25 2005-01-06 Crucell Holland B.V. Binding molecules for the treatment of myeloid cell malignancies
PL2314620T3 (pl) 2004-05-27 2013-11-29 Crucell Holland Bv Sposób identyfikowania cząsteczek wiążących zdolnych do neutralizowania wirusa wścieklizny
JP4852046B2 (ja) * 2004-10-12 2012-01-11 クルセル ホランド ベー ヴェー 癌の治療及び検出に用いる結合分子
EP1812067B1 (de) 2004-11-11 2012-03-21 Crucell Holland B.V. Zusammensetzungen gegen das sars-coronavirus und ihre verwendungen
CA2591665C (en) 2004-12-20 2015-05-05 Crucell Holland B.V. Binding molecules capable of neutralizing west nile virus and uses thereof
US20060235795A1 (en) * 2005-04-19 2006-10-19 Microsoft Corporation Secure network commercial transactions
CA2608058C (en) 2005-05-12 2013-09-10 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
AU2006290736B2 (en) 2005-09-15 2011-09-15 Crucell Holland B.V. Method for preparing immunoglobulin libraries
EP1963494B1 (de) * 2005-11-29 2014-10-08 The Trustees of The University of Pennsylvania Diagnostische phagenpartikelreagentien
US8227242B2 (en) * 2005-12-07 2012-07-24 Los Alamos National Security, Llc Plasmids and packaging cell lines for use in phage display
EP2027155B1 (de) 2006-06-06 2016-01-27 Crucell Holland B.V. Menschliche bindende moleküle mit abtötungswirkung gegen staphylokokken und ihre verwendung
CN101460518B (zh) 2006-06-06 2012-08-22 克鲁塞尔荷兰公司 针对肠球菌和金黄色葡萄球菌具有杀伤活性的人结合分子及其应用
EP2450379B1 (de) 2006-09-07 2015-11-04 Crucell Holland B.V. Zur Neutralisierung des Influenzavirus H5N1 fähige humane Bindungsmoleküle sowie deren Verwendungen
CA2663388C (en) 2006-09-07 2017-01-17 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
US9150849B2 (en) 2007-11-02 2015-10-06 The Scripps Research Institute Directed evolution using proteins comprising unnatural amino acids
SG176003A1 (en) 2009-05-11 2011-12-29 Crucell Holland Bv Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof
ES2608321T3 (es) 2011-07-14 2017-04-07 Janssen Vaccines & Prevention B.V. Moléculas de unión humanas capaces de neutralizar virus de la gripe A del grupo filogenético 1 y del grupo filogenético 2 y virus de la gripe B
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
MY170407A (en) 2012-03-08 2019-07-27 Crucell Holland Bv Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
ES2740749T3 (es) 2012-04-20 2020-02-06 Merus Nv Métodos y medios para la producción de moléculas heterodiméricas similares a Ig
US11066460B2 (en) 2015-11-25 2021-07-20 Eli Lilly And Company Phage display vectors and methods of use
WO2020180971A1 (en) * 2019-03-04 2020-09-10 The Texas A&M University System Methods of making and utilizing amber-obligated phage display libraries

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9500851D0 (en) * 1995-01-17 1995-03-08 Bionvent International Ab Method of selecting specific bacteriophages
EP1266963A1 (de) 2001-06-15 2002-12-18 Crucell Holland B.V. Chimäre Phagen
DK1402025T3 (da) * 2001-06-15 2006-06-06 Crucell Holland Bv Kimære fager
US7070926B2 (en) 2001-06-15 2006-07-04 Crucell Holland B.V. Chimaeric phages

Also Published As

Publication number Publication date
US7901919B2 (en) 2011-03-08
WO2002103012A1 (en) 2002-12-27
ATE317009T1 (de) 2006-02-15
EP1402025A1 (de) 2004-03-31
AU2002345421B2 (en) 2006-11-16
CA2449071C (en) 2008-12-16
US20050014261A1 (en) 2005-01-20
EP1402025B1 (de) 2006-02-01
DK1402025T3 (da) 2006-06-06
DE60209010T2 (de) 2006-09-28
ES2257560T3 (es) 2006-08-01
US20090017521A1 (en) 2009-01-15
CA2449071A1 (en) 2002-12-27
US7329530B2 (en) 2008-02-12
NZ529465A (en) 2005-05-27

Similar Documents

Publication Publication Date Title
DE60209010D1 (de) Chimäre phagen
NZ513153A (en) Selection of proteins using RNA-protein fusions
AU2001261499A1 (en) Methods of detecting interactions between proteins, peptides or libraries thereof using fusion proteins
AU1548795A (en) Bacterial receptor structures
NZ521396A (en) Fusion proteins comprising two or more Neisseria polypeptides
GB2338237A (en) In vitro peptide or protein expression library
WO2003020916A8 (en) Spider silk protein encoding nucleic acids, polypeptides, antibodies and method of use thereof
DE69737683D1 (de) Antikörper gegen die ed-b domäne von fibronektin, ihre herstellung und verwendungen
WO2003102157A3 (en) Synthetic antibody phage libraries
AU2002351239A1 (en) Antibody to latent membrane proteins and uses thereof
EP1847549A3 (de) Polyproteinkonstrukte des Papillomavirus
AU2002320317A1 (en) Novel mesogens and methods for their synthesis and use
WO2002018948A3 (en) Differentially expressed epitopes and uses thereof
WO2000056901A3 (en) Linear and circular expression elements
WO2003062402A3 (en) Use of collections of binding sites for sample profiling and other applications
ATE361286T1 (de) Borrelidin-derivate und ihre medizinische anwendung
BRPI0413426A (pt) antagonistas de receptor novo
AU2002235884A1 (en) Method for the identification of extracellular domains of the epstein barr virus (ebv), tumor-associated latent membrane proteins and for the selection of antibody reagents reactive therewith
ATE424457T1 (de) Menschliche stra6 polypeptide
ATE406449T1 (de) Antigene und vektoren für impfung
IL145689A0 (en) Methods
WO1999003993A3 (en) Suppressors of cytokine signaling; related reagents
DK1274853T3 (da) Materialer og fremgangsmåder, der angår immunreaktioner på fusionsproteiner
WO2003020005A3 (en) Lp mammalian proteins; related reagents
AU2003302133A1 (en) Uses of ble proteins and antibiotics from the bleomycin family

Legal Events

Date Code Title Description
8364 No opposition during term of opposition